Last update 21 Nov 2024

Deucravacitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Deucravacitinib (USAN)
+ [4]
Target
Mechanism
TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (09 Sep 2022),
RegulationSpecial Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC20H22N8O3
InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N
CAS Registry1609392-27-9

External Link

KEGGWikiATCDrug Bank
D11817---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Erythrodermic psoriasis
JP
26 Sep 2022
Psoriasis vulgaris
JP
26 Sep 2022
Pustular psoriasis
JP
26 Sep 2022
Plaque psoriasis
US
09 Sep 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Arthritis, PsoriaticPhase 3
HU
13 Jul 2021
Arthritis, PsoriaticPhase 3
US
13 Jul 2021
Arthritis, PsoriaticPhase 3
GB
13 Jul 2021
Arthritis, PsoriaticPhase 3
CO
13 Jul 2021
Arthritis, PsoriaticPhase 3
CL
13 Jul 2021
Arthritis, PsoriaticPhase 3
IT
13 Jul 2021
Plaque psoriasisPhase 3
PR
26 Jul 2018
Plaque psoriasisPhase 3
IL
26 Jul 2018
Plaque psoriasisPhase 3
NZ
26 Jul 2018
PsoriasisPhase 2
JP
10 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
67
(sqcjxwdtcq) = okoovgeiyo pouyooulkd (egzwmvbbes, zjmhhlhlhg - eqzcyduunu)
-
24 Sep 2024
(Ulcerative Colitis)
(sqcjxwdtcq) = dmkkeiwjgj pouyooulkd (egzwmvbbes, zgctkhrapj - gszpwfuamm)
Phase 2
38
(BMS-986165 12 mg BID)
lufznzntgo(fiqxpbyhav) = xvzuctjazb ohjkegvmls (fkjzizernr, fmovqkwycw - xlakjrugts)
-
12 Jul 2024
Placebo
(Placebo BID PO)
lufznzntgo(fiqxpbyhav) = vsymzhegxr ohjkegvmls (fkjzizernr, fylfnhnqjd - wtoxxuyhfg)
Phase 2
239
Placebo
sbvwquzros(xxhoonxwao) = rviadfdvjp kbivdjogai (prztrolmsu, useirgsqsm - lgoqfrsvaj)
-
03 Jul 2024
Phase 3
Plaque psoriasis
Maintenance
513
(achieved PASI 75 at week 16)
gmatnavraf(spbrzxjynp) = kpiostyksq eafswyvsgq (lqdxkjizkw, NE - NE)
Positive
05 Jun 2024
Deucravacitinib 6 mg QD
(achieved PASI 75 at week 24)
(rvtmkbviht) = ydfnnslawl lhdsurfbir (qnpzckhywf, NE - NE)
Phase 2
101
(radkifrfcg) = eqhwqxfrci wnvseeltxi (xxrmfzrklk )
Positive
05 Jun 2024
(radkifrfcg) = uknkumjwsi wnvseeltxi (xxrmfzrklk )
Phase 2
Systemic Lupus Erythematosus
antinuclear antibody | anti-double-stranded DNA | anti-Smith antibody
363
(bbtrbhbklo) = ufmrocpvrd hbezwjomhx (hrglqrmcjl, 2.7)
Positive
05 Jun 2024
(bbtrbhbklo) = lrqzrnilhw hbezwjomhx (hrglqrmcjl, 2.6)
Not Applicable
-
tbduumzimw(jgjqdyflil) = culmecdtsa stavyesxmx (gsmckmaezu )
-
05 Jun 2024
tbduumzimw(jgjqdyflil) = shhmmtodtp stavyesxmx (gsmckmaezu )
Phase 2
Salivary Gland Adenoma, Pleomorphic
CRP | LEI | LDI ...
203
iivyvjgkru(zpwuxzkpet) = ebxemmnkfx jlrljtlsrt (sdadzccfuy )
Positive
05 Jun 2024
iivyvjgkru(zpwuxzkpet) = juoisufqvo jlrljtlsrt (sdadzccfuy )
Phase 3
1,221
Sotyktu (deucravacitinib) 6 mg
(ctgoetlnip) = wymthzrfcb tgnrovzwtc (nnkgqwvlxa )
Positive
16 May 2024
Phase 3
1,519
(hggqgipfcn) = Exposure-adjusted incidence rates (EAIRs) per 100 person-years were similar at 1 year and 2 years for any AEs (229.2 vs. 154.4, respectively), serious AEs (5.7 vs. 6.1), discontinuations (4.4 vs. 2.8), deaths (0.2 vs. 0.4), serious infections (1.7 vs. 2.6), herpes zoster (0.9 vs. 0.8), major adverse cardiovascular events (0.3 vs. 0.4), venous thromboembolic events (0.2 vs. 0.1) and malignancies (1.0 vs. 0.9) zyzykwchyw (jynpgglpaw )
Positive
16 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free